The 3xTg-AD Mouse Model: Reproducing and Modulating Plaque and Tangle Pathology

[1]  J. Rajadas,et al.  Aβ peptide conformation determines uptake and interleukin-1α expression by primary microglial cells , 2009, Neurobiology of Aging.

[2]  F. LaFerla,et al.  Aβ inhibits the proteasome and enhances amyloid and tau accumulation , 2008, Neurobiology of Aging.

[3]  H. Federoff,et al.  Reduced Pathology and Improved Behavioral Performance in Alzheimer's Disease Mice Vaccinated With HSV Amplicons Expressing Amyloid-β and Interleukin-4. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[4]  L. Mucke,et al.  Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model , 2007, Science.

[5]  F. LaFerla,et al.  Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles. , 2007, The American journal of pathology.

[6]  Frank M LaFerla,et al.  Dietary Docosahexaenoic Acid and Docosapentaenoic Acid Ameliorate Amyloid-β and Tau Pathology via a Mechanism Involving Presenilin 1 Levels , 2007, The Journal of Neuroscience.

[7]  J. D. McGaugh,et al.  Learning Decreases Aβ*56 and Tau Pathology and Ameliorates Behavioral Decline in 3xTg-AD Mice , 2007, The Journal of Neuroscience.

[8]  F. LaFerla,et al.  Reduction of Soluble Aβ and Tau, but Not Soluble Aβ Alone, Ameliorates Cognitive Decline in Transgenic Mice with Plaques and Tangles* , 2006, Journal of Biological Chemistry.

[9]  I. Ferrer,et al.  A&bgr; Species Removal After A&bgr;42 Immunization , 2006, Journal of neuropathology and experimental neurology.

[10]  J. D. McGaugh,et al.  Glucocorticoids Increase Amyloid-β and Tau Pathology in a Mouse Model of Alzheimer’s Disease , 2006, The Journal of Neuroscience.

[11]  F. LaFerla,et al.  M1 Receptors Play a Central Role in Modulating AD-like Pathology in Transgenic Mice , 2006, Neuron.

[12]  J. Hardy,et al.  Has the amyloid cascade hypothesis for Alzheimer's disease been proved? , 2006, Current Alzheimer research.

[13]  W. Klein,et al.  Temporal Profile of Amyloid-β (Aβ) Oligomerization in an in Vivo Model of Alzheimer Disease , 2006, Journal of Biological Chemistry.

[14]  C. Mathers,et al.  Global prevalence of dementia: a Delphi consensus study , 2005, The Lancet.

[15]  F. LaFerla,et al.  Early correlation of microglial activation with enhanced tumor necrosis factor-alpha and monocyte chemoattractant protein-1 expression specifically within the entorhinal cortex of triple transgenic Alzheimer's disease mice , 2005, Journal of Neuroinflammation.

[16]  F. LaFerla,et al.  Lipopolysaccharide-Induced Inflammation Exacerbates Tau Pathology by a Cyclin-Dependent Kinase 5-Mediated Pathway in a Transgenic Model of Alzheimer's Disease , 2005, The Journal of Neuroscience.

[17]  M. Goedert.  Tau gene mutations and their effects , 2005, Movement disorders : official journal of the Movement Disorder Society.

[18]  Takashi Morihara,et al.  A Diet Enriched with the Omega-3 Fatty Acid Docosahexaenoic Acid Reduces Amyloid Burden in an Aged Alzheimer Mouse Model , 2005, The Journal of Neuroscience.

[19]  J. D. McGaugh,et al.  Intraneuronal Aβ Causes the Onset of Early Alzheimer’s Disease-Related Cognitive Deficits in Transgenic Mice , 2005, Neuron.

[20]  F. LaFerla,et al.  Chronic nicotine administration exacerbates tau pathology in a transgenic model of Alzheimer's disease. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[21]  Takashi Morihara,et al.  Docosahexaenoic Acid Protects from Dendritic Pathology in an Alzheimer's Disease Mouse Model , 2004, Neuron.

[22]  J. Trojanowski,et al.  Proteasome Inhibition Stabilizes Tau Inclusions in Oligodendroglial Cells that Occur after Treatment with Okadaic Acid , 2003, The Journal of Neuroscience.

[23]  M. Mattson,et al.  Triple-Transgenic Model of Alzheimer's Disease with Plaques and Tangles Intracellular Aβ and Synaptic Dysfunction , 2003, Neuron.

[24]  B. Dubois,et al.  Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization , 2003, Neurology.

[25]  F. Shie,et al.  Early intraneuronal Aβ deposition in the hippocampus of APP transgenic mice , 2003 .

[26]  L. Serpell,et al.  Proteasomal degradation of tau protein , 2002, Journal of neurochemistry.

[27]  Tony Wyss-Coray,et al.  Inflammation in Neurodegenerative Disease—A Double-Edged Sword , 2002, Neuron.

[28]  A. Fisher,et al.  AF150(S) and AF267B , 2002, Journal of Molecular Neuroscience.

[29]  Arthur F Kramer,et al.  Achieving and maintaining cognitive vitality with aging. , 2002, Mayo Clinic proceedings.

[30]  E. Perry,et al.  Chronic nicotine treatment reduces β‐amyloidosis in the brain of a mouse model of Alzheimer's disease (APPsw) , 2002, Journal of neurochemistry.

[31]  W. K. Cullen,et al.  Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo , 2002, Nature.

[32]  L. Lue,et al.  Microglial chemotaxis, activation, and phagocytosis of amyloid β-peptide as linked phenomena in Alzheimer's disease , 2001, Neurochemistry International.

[33]  R. Nitsch,et al.  Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils , 2001, Science.

[34]  D. Dickson,et al.  Enhanced Neurofibrillary Degeneration in Transgenic Mice Expressing Mutant Tau and APP , 2001, Science.

[35]  J. Troncoso,et al.  Intraneuronal abeta-amyloid precedes development of amyloid plaques in Down syndrome. , 2001, Archives of pathology & laboratory medicine.

[36]  J. Hardy,et al.  Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease , 2000, Nature.

[37]  Ralph A. Nixon,et al.  Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease , 2000, Nature.

[38]  N. Bazan,et al.  Neuroinflammatory Signaling Upregulation in Alzheimer's Disease , 2000, Neurochemical Research.

[39]  A. Fisher.  Therapeutic strategies in Alzheimer's disease: M1 muscarinic agonists. , 2000, Japanese journal of pharmacology.

[40]  W. Griffin,et al.  Interleukin-1 Promotes Expression and Phosphorylation of Neurofilament and tau Proteins in Vivo , 2000, Experimental Neurology.

[41]  R. Motter,et al.  Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse , 1999, Nature.

[42]  T. Morgan,et al.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[43]  Y. Ihara,et al.  Astrocytes containing amyloid beta-protein (Abeta)-positive granules are associated with Abeta40-positive diffuse plaques in the aged human brain. , 1998, The American journal of pathology.

[44]  D. Coakley,et al.  Hypothalamic-pituitary-adrenal axis dysfunction in Alzheimer's disease: lack of association between longitudinal and cross-sectional findings. , 1998, The American journal of psychiatry.

[45]  B. Sommer,et al.  Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[46]  H. Stähelin,et al.  Does smoking protect from Alzheimer’s disease? Alzheimer-type changes in 301 unselected brains from patients with known smoking history , 1997, Acta Neuropathologica.

[47]  D. Borchelt,et al.  Accelerated Amyloid Deposition in the Brains of Transgenic Mice Coexpressing Mutant Presenilin 1 and Amyloid Precursor Proteins , 1997, Neuron.

[48]  G. Jicha,et al.  Alz‐50 and MC‐1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau , 1997, Journal of neuroscience research.

[49]  J. Hardy,et al.  Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1 , 1996, Nature.

[50]  S. Younkin,et al.  Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice , 1996, Science.

[51]  G. Schellenberg,et al.  Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease , 1996, Nature Medicine.

[52]  L. Mucke,et al.  Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein , 1995, Nature.

[53]  S. Younkin,et al.  An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. , 1994, Science.

[54]  A. Nordberg,et al.  Characterization of muscarinic receptor subtypes in Alzheimer and control brain cortices by selective muscarinic antagonists , 1992, Brain Research.

[55]  J. Hardy,et al.  Alzheimer's disease: the amyloid cascade hypothesis. , 1992, Science.

[56]  S. DeKosky,et al.  Quantitation of synaptic density in the septal nuclei of young and aged Fischer 344 rats , 1991, Neurobiology of Aging.

[57]  W. Griffin,et al.  Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[58]  K. Davis,et al.  Cortisol and Alzheimer's disease, I: Basal studies. , 1986, The American journal of psychiatry.

[59]  G. Glenner,et al.  Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. , 1984, Biochemical and biophysical research communications.

[60]  P. Mcgeer,et al.  Aging, Alzheimer's disease, and the cholinergic system of the basal forebrain , 1984, Neurology.

[61]  P. Davies,et al.  SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE , 1976, The Lancet.

[62]  M. Schultzberg,et al.  β-amyloid protein structure determines the nature of cytokine release from rat microglia , 2007, Journal of Molecular Neuroscience.

[63]  A. Fisher,et al.  M1 muscarinic agonists can modulate some of the hallmarks in Alzheimer’s disease , 2007, Journal of Molecular Neuroscience.

[64]  F. LaFerla,et al.  A dynamic relationship between intracellular and extracellular pools of Abeta. , 2006, The American journal of pathology.

[65]  D. Campion,et al.  APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy , 2006, Nature Genetics.

[66]  R. Horuk,et al.  Chemokine and chemokine receptor expression in the central nervous system. , 1999, Journal of neurovirology.

[67]  J. Hardy,et al.  Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes , 1998, Nature Medicine.

[68]  J. Hardy,et al.  Amyloid deposition as the central event in the aetiology of Alzheimer's disease. , 1991, Trends in pharmacological sciences.

[69]  N. Bazan,et al.  Dietary omega-3 fatty acids and accumulation of docosahexaenoic acid in rod photoreceptor cells of the retina and at synapses. , 1990, Upsala journal of medical sciences. Supplement.